Cellectis S.A. is a biotech company that develops immuno-oncology products based on gene-edited T-cells to fight cancer cells. It has two segments: Therapeutics and Plants, and the company is currently developing multiple T-cell product candidates for the treatment of various hematologic malignancies, including acute myeloid leukemia and multiple myeloma. Cellectis S.A. has collaborations with various other biotech companies to enhance its research and development process.